Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

By Richard A. Rudick, W. Stuart, Peter A. Calabresi, Christian Confavreux, S. Galetta, E. Radue, F. Lublin, B. Weinstock-Guttman, D. Wynn, F. Lynn and 2 more. New England Journal of Medicine, 2006

1,340 citations recorded by the source corpus.

Subfields: Neurology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/1fe0b466fb9bc56b1f78e213062a3dc979542fcf

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. You-Shan Feng
2. T. Kohlmann
3. S. Meyer-Moock
4. M. Maeurer
5. F. Dippel

Citations in the corpus

• Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis (2013, background): “Recent studies usually also include the MSFC-score as an endpoint in clinical trials [39-41].”